Evaluation of the therapeutic efficacy of a VEGFR2-blocking antibody using sodium-iodide symporter molecular imaging in a tumor xenograft model
Introduction
Tumor angiogenesis is essential for the growth and metastasis of solid tumors [1], [2]. A number of angiogenic inhibitors have been developed to treat tumors, and many of these inhibitors are directed against vascular endothelial growth factor (VEGF) or its receptors (VEGFRs), which are considered key regulators of tumor angiogenesis [3], [4], [5], [6]. DC101 is a monoclonal antibody that targets VEGFR2 and has previously been shown to have antitumor effects in vivo [7], [8], [9], [10].
Tumor imaging is important to monitor tumor progression and proliferative changes after therapy. Molecular imaging based on reporter gene expression is suitable for tumor imaging in living subjects. Molecular imaging enables the visualization, characterization, and quantification of biologic processes in living subjects [11], [12]. Reporter genes are of considerable interest to image molecular events in small animals. Noninvasive reporter gene expression imaging offers opportunities to understand tumor progression, metastasis, and therapy in whole animals [12], [13], [14].
The human sodium/iodide symporter (hNIS) gene is a promising reporter gene. Recently, the hNIS gene has been intensively investigated with regard to the diagnosis and treatment of thyroid diseases [15], [16], [17], [18], [19]. As compared with conventional imaging reporter genes, an NIS gene has the merit of wide availability of substrates, including radioiodine and 99mTc-pertechnetate, which have been used commonly in clinical fields. Moreover, this gene is unlikely to influence the underlying cell biochemistry, and iodide is not metabolized in most tissues [20]. The hNIS gene can be transfected into specific cancer cells, and tumor models of gene transfer can be monitored visually to assess tumor progression and therapeutic effects using radioiodine or 99mTc-pertechnetate after drug administration [12], [20]. The effectiveness of NIS as a noninvasive reporter gene has already been demonstrated by several studies of tumor models of gene transfer [21], [22], [23], [24], [25], [26].
In this study, we investigated the potential of molecular imaging to evaluate the therapeutic effect of a specific antibody, DC101, in vivo.
Section snippets
Materials
All laboratory chemicals, unless indicated otherwise, were of molecular biology grade and were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Invitrogen (Carlsbad, CA, USA). Na125I was obtained from Perkin Elmer Life Sciences (Boston, MA, USA). 99mTc-pertechnetate was eluted from a technetium generator produced by Samyoung Unitech (Seoul, Korea).
Tumor cell culture and transfected cell line generation
MDA-MB-231 breast cancer cells were cultured in DMEM (Dulbecco's Modified Eagle Medium) medium containing 100 IU/ml penicillin, 100 μg/ml
Radioactivity increased according to cell number
We established an MDA-MB-231-hNIS cell line that stably expresses hNIS. Fig. 1 shows the results for 125I and 99mTc-pertechnetate uptake, both radiotracers transported by hNIS, in a dilution series of MDA-MB-231 and MDA-MB-231-hNIS cells. As the number of MDA-MB-231-hNIS cells increased, so did the uptake of 125I (Fig. 1A). Increased radioactivity was also observed in gamma camera images (Fig. 1B). Similarly, as the number of MDA-MB-231-hNIS cells increased, so did the accumulation of 99m
Discussion
Molecular imaging that enables the visualization, characterization and quantification of biologic processes in living subjects is highly valuable for preclinical tumor research and especially for the evaluation of new antitumor drugs.
Here, we describe a monitoring strategy using a reporter gene transfected into tumor cells to evaluate the therapeutic efficacy, including the appropriate dose and administration route, of an antibody. We demonstrated, through the use of tumor xenograft models
Conclusions
We determined the necessary therapeutic dose of an anti-angiogenesis antibody, DC101, for therapy by intravenous injection in an in vivo mouse model. We used molecular imaging of hNIS to evaluate the dose-dependent therapeutic efficacy of DC101. Molecular imaging evaluation systems are powerful tools that can be used to aid the development of effective therapeutic antibodies.
Acknowledgments
This study was supported by grants from Nuclear R&D program through the Korea Science and Engineering Foundation funded by the Ministry of Science & Technology (20090062447) and the National R&D Program for Cancer Control, Ministry of Health, Welfare and Family affairs, Republic of Korea (0620220 and 0720420). This article was also supported by research funds of Chonbuk National University in 2009.
References (36)
- et al.
Vascular endothelial growth factor and its receptors
Cytokine Growth Factor Rev
(1996) - et al.
Molecular-genetic imaging based on reporter gene expression
J Nucl Med
(2008) Noninvasive imaging of reporter gene expression in living subjects
Adv Cancer Res
(2004)- et al.
Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal
Mol Ther
(2004) - et al.
Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101
Neoplasia
(2004) - et al.
Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors
Radiother Oncol
(2004) - et al.
In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter
Pancreatology
(2007) Angiogenesis in cancer, vascular, rheumatoid and other disease
Nat Med
(1995)- et al.
Angiogenesis in cancer and other diseases
Nature
(2000) - et al.
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy
Curr Med Chem Anticancer Agents
(2003)
Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis
Cancer Res
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
Nature
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
Cancer Res
Flk-1 as a target for tumor growth inhibition
Cancer Res
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
Cancer Metastasis Rev
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
Cancer Res
In vivo molecular-genetic imaging
J Cell Biochem Suppl
Molecular imaging: reporter gene imaging
Handb Exp Pharmacol
Cited by (12)
Comparative untargeted proteomic analysis of ADME proteins and tumor antigens for tumor cell lines
2018, Acta Pharmaceutica Sinica BCitation Excerpt :As a result, overexpressed membrane transporters, receptors and tumor antigens become targets to achieve a more specific treatment or discover precision medicine for cancer therapy5. Recently, utilizing overexpressed membrane receptors as cancer-targeting agents to deliver a chemically or genetically conjugated toxic molecule has gained increasing attentions for the therapeutic efficacy6,7. Such liganddrug conjugates or antibody drug conjugates (ADCs) that consist of monoclonal antibodies attached to biologically active drugs through chemical linkers7.
Application of molecular imaging technology in evaluating the inhibiting effect of apigenin in vivo on subcutaneous hepatocellular carcinoma
2017, Biochemical and Biophysical Research CommunicationsCitation Excerpt :In recent years, optical molecular imaging has emerged as an important tool of technologies to advance our understanding of disease mechanisms and accelerate drug discovery [15,16]. It can especially enhance the visualization, characterization and quantification of biological processes in living subjects [17,18]. These features are highly valuable for preclinical tumor research especially for the assessment of new anti-tumor drugs.
SPECT/PET Imaging with Technetium, Gallium, Copper, and Other Metallic Radionuclides
2013, Comprehensive Inorganic Chemistry II (Second Edition): From Elements to Applications